Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) Income from Continuing Operations (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Income from Continuing Operations for 9 consecutive years, with 85431000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations fell 35.12% to 85431000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 334000.0 through Dec 2025, down 100.12% year-over-year, with the annual reading at 362000.0 for FY2025, 100.13% down from the prior year.
  • Income from Continuing Operations hit 85431000.0 in Q4 2025 for Protagonist Therapeutics, up from 39339000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 207366000.0 in Q1 2024 to a low of 40959000.0 in Q2 2022.
  • Historically, Income from Continuing Operations has averaged 3443100.0 across 5 years, with a median of 30994000.0 in 2021.
  • Biggest five-year swings in Income from Continuing Operations: crashed 335.45% in 2021 and later soared 714.87% in 2024.
  • Year by year, Income from Continuing Operations stood at 88890000.0 in 2021, then crashed by 138.55% to 34265000.0 in 2022, then surged by 179.78% to 27335000.0 in 2023, then soared by 381.7% to 131674000.0 in 2024, then plummeted by 35.12% to 85431000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for PTGX at 85431000.0 in Q4 2025, 39339000.0 in Q3 2025, and 34771000.0 in Q2 2025.